Straits Times Index
3,324.79 -1.49 (-0.04%) Nikkei
39,688.96 +515.81 (+1.32%) Hang Seng
18,134.49 +61.59 (+0.34%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,637.17 +297.17 (+0.48%) CMC Crypto 200
1,280.67 +31.55 (+2.53%)
ARWR Jun 2024 45.000 put
| Previous close | 14.20 |
| Open | N/A |
| Bid | 10.00 |
| Ask | 13.50 |
| Strike | 45.00 |
| Expiry date | 2024-06-21 |
| Day's range | 14.20 - 14.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 75 |
Business WireArrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
PASADENA, Calif., June 25, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-2 s
Business WireArrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
PASADENA, Calif., June 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually.
BenzingaWhy Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS). FCS is a rare metabolic disease that prevents the body from digesting fats. Related: What Arrowhead Pharmaceutical’s Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder The study met the primary endpoint of lowering triglycerides and all key sec
